AZN - AstraZeneca AB Debt to Book Capitalization Ratio

AstraZeneca PLC (AZN) relies on manufacturing capacities in the US, Sweden, and the UK to produce oncology drugs. This debt-to-market cap chart illustrates the financial leverage dynamics, where the value 0.66 represents the current magnitude. Growth is driven by M&A deals with biotech firms and the implementation of AI robotics to automate laboratory research and accelerate the discovery of new formulas.

astrazeneca.com - AZN Debts to Book Capitalization (period 07/04/2022 - 10/27/2026)

AstraZeneca Plc (AZN) - metric breakdowns and financial figures

- price and consensus price forecast:

Price Chart AstraZeneca PLC|AZN - Fair Value Consensus

- market capitalization data:

Market Value AstraZeneca Corp.|AZN - Real Price to Acquire Entire Company

- book capitalization data:

Book Value per Share AstraZeneca|AZN - Book Capitalization|Market Cap to Net Assets Ratio astrazeneca.com|AZN - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital AstraZeneca PLC|AZN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity AstraZeneca AB|AZN - Company Cumulative Debt|Debt to Book Capitalization Ratio AstraZeneca Corp.

Summary company analytics:AZN (AstraZeneca PLC)

This metric measures financial leverage by comparing total liabilities to the current market value of equity, enabling real-time tracking of the balance between debt load and investment demand. The high margins of the oncology portfolio at AstraZeneca PLC (AZN) minimize debt service risks; therefore, the history of the ratio of financial debt to book capitalization serves as an indicator of the business's resilience to market volatility.

Competitors of AstraZeneca PLC